Dr. Mojgan Najafzadeh is an Assistant Professor in Medical Science with a passion for bringing cancer-treatment technologies to market. Over the past 15 years in the medical technology sector, she has engaged deeply with multifaceted projects. In 2011, she worked on the Lymphocyte Genome Sensitivity (LGS) assay project. As part of efforts to bring the LGS assay to market, she helped launch a spin-out company named OncaScan. This venture successfully secured funding amounting to £1,400,000, which was instrumental in enhancing the assay's capabilities. This initiative has enabled her to play a pivotal role at every stage, starting from its initial conception and advancing through various phases, including rigorous research and development, patenting processes, and ultimately launching the product into the competitive marketplace. Now Mojgan is turning her efforts to developing OncaNova’s diagnostic and treatment platform. The proprietary miRNA of OncaNova directly selectively kills cancer cells, spares healthy tissue, and triggers “danger signals” that alert the immune system. OncaNova is uniquely positioned to become a category-defining biotech, with first-in-class potential across multiple cancer types.